R&D | October 12, 2025
Merck unveils new HIV treatment and prevention data at EACS 2025
Merck will showcase results in innovative solutions in HIV treatment and prevention
Merck will showcase results in innovative solutions in HIV treatment and prevention
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
The FDA set a target action date of April 28, 2026, under the Prescription Drug User Fee Act
Subscribe To Our Newsletter & Stay Updated
